Taken together, our data demonstrate that Hsp90 inhibition effectively reduces the cell viability and phosphorylation of STAT3 mutated primary LGL-leukemia cells even in absence of cytokine stimulation and its effect is further increased when JAK/STAT signaling is activated with IL2 and IL15. The gene discussed is IL2; the disease is leukemia.